European Journal of Heart Failure最新文献

{"title":"Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study","authors":"Stephen J. Greene, Stefano Corda, Ciaran J. McMullan, Giovanni Palombo, Christina Schooss, Vanja Vlajnic, Katrin Walkamp, Michele Senni","doi":"10.1002/ejhf.3699","DOIUrl":"https://doi.org/10.1002/ejhf.3699","url":null,"abstract":"AimsIn clinical practice, simplifying the number of medication titration steps while maintaining safety may improve the likelihood of patients with heart failure (HF) achieving target doses of guideline‐directed medical therapy (GDMT). The VELOCITY study examined whether removing the 2.5 mg initiation step for vericiguat, and instead initiating therapy at 5 mg daily, would be safe and well‐tolerated.Methods and resultsVELOCITY was a prospective, 2‐week, single‐arm, open‐label phase 2b study that enrolled patients with chronic HF with ejection fraction <45%, with or without a recent (≤6 or >6 months) worsening HF (WHF) event. Patients with systolic blood pressure <100 mmHg, recent symptomatic hypotension, and recent change in background GDMT or diuretic dosing were excluded. Participants were initiated on vericiguat 5 mg daily and followed for the primary endpoint, defined as completion of 2‐week period with maximum 1‐day interruption and without moderate to severe symptomatic hypotension between Visit 1 (Day 1) and Visit 2 (Day 14). Among 106 study patients (mean age 67 years, 28% female), 50% had recent WHF. Background GDMT included 54% prescribed angiotensin receptor–neprilysin inhibitors and 81% prescribed sodium–glucose cotransporter 2 inhibitors. The primary tolerability endpoint was met in 93.4% of patients, including 90.6% of patients in the WHF group and 96.2% of patients in the non‐WHF group. Tolerability of initiating vericiguat 5 mg was generally consistent across the pre‐specified sensitivity and secondary endpoints. When comparing patients initiating vericiguat 2.5 mg daily in VICTORIA with those starting vericiguat 5 mg daily in VELOCITY, the proportion meeting the VELOCITY primary tolerability endpoint was 97.2% in VICTORIA versus 93.4% in VELOCITY.ConclusionsIn the prospective VELOCITY study of patients with chronic HF with ejection fraction <45% who were well‐treated with background GDMT, >9 of 10 patients safely tolerated initiation of vericiguat at the 5 mg/day dose. Findings were generally consistent regardless of recent history of WHF. In the context of safety and tolerability data from prior vericiguat studies, VELOCITY supports a potential update in clinical guidance to include a 5 mg starting dose of vericiguat among patients without recent hypotension.Clinical Trials Registration: ClinicalTrials.gov NCT06195930.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"97 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial.","authors":"Stefan D Anker,Michele Robertson,John J V McMurray,Pardeep S Jhund,Claire White,Chante Reid,Sunil Bhandari,Ken Farrington,Philip A Kalra,Khawaja M Talha,Patrick B Mark,Charles R V Tomson,David C Wheeler,Chris G Winearls,Iain C Macdougall,Ian Ford","doi":"10.1002/ejhf.3670","DOIUrl":"https://doi.org/10.1002/ejhf.3670","url":null,"abstract":"AIMSIn the PIVOTAL trial, a proactive high-dose regimen of intravenous iron sucrose, compared to a lower-dose reactive regimen, reduced the risk of first and recurrent events of the primary endpoint in haemodialysis patients. We present the various approaches of recurrent event analyses for the primary endpoint and for the composite of cardiovascular (CV) death or heart failure hospitalization and their non-fatal components.METHODS AND RESULTSPatients were randomized to a proactive maintenance dose of iron sucrose (average 264 mg/month) or a reactive treatment regimen (average 145 mg/month). We compared the results of time-to-first event analyses with recurrent event analysis using the negative binomial model and methods proposed by Wei-Lin-Weissfeld, Andersen and Gill, Lin, Wei, Yang and Ying [LWYY], Mao and Lin, and Rondeau and colleagues. The 2141 haemodialysis patients were followed for a median of 2.1 years and experienced 936 primary recurrent events, which is 42% higher than the number of 658 first events. Proactive regimen patients had 429 primary events (19.4/100 patient-years) compared with 507 events in the reactive regimen patients (24.6/100 patient-years) (rate ratio 0.77, 95% confidence interval [CI] 0.66-0.92, p = 0.0027, LWYY). Recurrent events were also reduced in the proactive regimen for the composite of CV mortality and heart failure hospitalizations (rate ratio 0.73, 95% CI 0.56-0.93, p = 0.013). Recurrent event analyses based on other approaches were very similar to those given above based on the method of LWYY.CONCLUSIONA higher dose of chronic intravenous iron therapy compared to a lower dose substantially reduced the total burden of important recurrent events of death and CV disease in patients with end-stage kidney disease receiving maintenance haemodialysis therapy.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"31 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides","authors":"Jerremy Weerts, Arantxa Barandiarán Aizpurua, Ravi B. Patel, Arno A. van de Bovenkamp, Hesam Amin, Sandra Sanders‐van Wijk, Sanne G.J. Mourmans, Anouk Achten, M. Louis Handoko, Antoni Bayés‐Genís, Hans‐Peter Brunner‐La Rocca, Sanjiv J. Shah, Christian Knackstedt, Vanessa P.M. van Empel","doi":"10.1002/ejhf.3651","DOIUrl":"https://doi.org/10.1002/ejhf.3651","url":null,"abstract":"AimsHeart failure with preserved ejection fraction (HFpEF) is common but diagnosing it remains cumbersome and complex. Left atrial (LA) enlargement and dysfunction is an important pathologic marker in HFpEF. We evaluated whether LA measures and circulating natriuretic peptides (NPs) could simplify HFpEF diagnosis as a first step.Methods and resultsA new, first‐step diagnostic approach to rule in HFpEF is presented using LA volume indexed for height<jats:sup>2</jats:sup> (LAViH2; cut‐off &gt;35.5 ml/m<jats:sup>2</jats:sup> in sinus rhythm, or &gt;38.6 ml/m<jats:sup>2</jats:sup> in atrial fibrillation) and NPs (as per the HFA‐PEFF major criterion). The LA/NP approach was derived from 443 patients with suspected of HFpEF (final diagnosis 84% HFpEF, 16% controls without heart failure), and validated in two independent cohorts (503 patients, 90% HFpEF; and 123 patients undergoing (exercise) right heart catheterization, 86% HFpEF). The LA/NP step identified 60% HFpEF patients with 88% specificity and 97% positive predictive value (PPV) (derivation cohort). Sequentially applying the LA/NP step, and if normal followed by either HFA‐PEFF or H<jats:sub>2</jats:sub>FPEF algorithm, reduced intermediate HFpEF likelihood scores compared to starting with the algorithms, decreasing additional diagnostic needs for HFpEF diagnosis by 27% (HFA‐PEFF) and 56% (H<jats:sub>2</jats:sub>FPEF). Validation cohorts confirmed the LA/NP approach (76–80% specificity, 92–97% PPV, and 21–57% reduction in intermediate scores). Replacing LAViH2 with LA reservoir strain showed comparable results.ConclusionA first‐step approach using enlarged LA volume and elevated NPs simplifies HFpEF diagnosis. This approach identifies most HFpEF patients with high specificity and substantially reduces the need for additional diagnostics by lowering intermediate HFA‐PEFF or H<jats:sub>2</jats:sub>FPEF scores.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"41 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home‐based urinary sodium monitoring via point‐of‐care testing for personalized diuretic titration in heart failure management: The EASY‐STOP study","authors":"Evelyne Meekers, Pieter Martens, Ruben Knevels, Marie Miseur, Athanasius Ezzat, François Croset, Jeroen Dauw, Henri Gruwez, Sebastiaan Dhont, Jonas Erzeel, Marnicq Van Es, Petra Nijst, Frederik H. Verbrugge, Matthias Dupont, Stefan Janssens, Wilfried Mullens","doi":"10.1002/ejhf.3693","DOIUrl":"https://doi.org/10.1002/ejhf.3693","url":null,"abstract":"AimsLoop diuretics alleviate symptoms in heart failure (HF), but despite recommendations for dynamic dosing, implementation in practice remains challenging. The EASY‐STOP trial investigated whether ambulatory urinary sodium monitoring using a point‐of‐care sensor could guide diuretic down‐titration.Methods and resultsThis prospective, single‐centre study enrolled 50 euvolaemic HF patients on stable guideline‐directed medical therapy for ≥3 months and receiving maintenance loop diuretic (≥20 mg furosemide equivalent daily). After a 1‐week baseline phase of daily self‐measured first‐void and post‐diuretic urinary sodium assessment, loop diuretics were gradually reduced by 50% and discontinued when ≤20 mg furosemide equivalents. Urinary monitoring continued for another 3 weeks. Successful down‐titration was defined as remaining congestion‐free (no rise in New York Heart Association class ≥I, oedema, pleural effusion, ascites, rise in right ventricular systolic pressure ≥10 mmHg, or worsening diastolic dysfunction ≥1 grade). Investigators and patients were blinded for urinary sodium analysis during the study. Patients were 75 (68–79) years old, had left ventricular ejection fraction 46 (± 11)%, estimated glomerular filtration rate 47 (35–65) ml/min and N‐terminal pro‐B‐type natriuretic peptide 899 (326–2558) ng/L. Among the 50 patients, 62 diuretic down‐titrations were performed, of which 34 (55%) were successful. Baseline urinary sodium before loop diuretic down‐titration was similar between groups. However, patients who successfully achieved down‐titration exhibited a significant increase in first‐void urinary sodium following down‐titration (53–74 mmol/L, <jats:italic>p</jats:italic> &lt; 0.001), whereas those requiring reinitiation showed no significant change (56–58 mmol/L, <jats:italic>p</jats:italic> = 0.331). A 10 mmol/L increase predicted successful down‐titration with 79.4% sensitivity and 78.6% specificity (area under the curve = 0.851).ConclusionsPoint‐of‐care urinary sodium monitoring may represent a non‐invasive and personalized approach to diuretic titration in HF management. Further trials are warranted to validate its clinical utility and long‐term benefits.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"4 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incident heart failure is common and underrecognized in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease","authors":"Kara Wegermann, Fouad Chouairi, Georgia Sofia Karachaliou, Carolyn Ahlers, Sandra Au, Kaela Miller, Tor Biering-Sørensen, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan, Marat Fudim","doi":"10.1002/ejhf.3697","DOIUrl":"https://doi.org/10.1002/ejhf.3697","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with heart failure (HF), independent of shared risk factors. Our aim was to describe the incidence of HF in patients with biopsy-proven MASLD.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"76 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144097671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials","authors":"Udo Bavendiek, Nele Henrike Thomas, Dominik Berliner, Xiaofei Liu, Johannes Schwab, Andreas Rieth, Lars S. Maier, Sven Schallhorn, Eleonora Angelini, Samira Soltani, Fabian Rathje, Mircea-Andrei Sandu, Welf Geller, Thomas Gaspar, Rainer Hambrecht, Marija Zdravkovic, Sebastian Philipp, Dragana Kosevic, Georg Nickenig, Daniel Scheiber, Sebastian Winkler, Peter Moritz Becher, Philipp Lurz, Martin Hülsmann, Maria von Karpowitz, Christoph Schröder, Barbara Neuhaus, Anika Seltmann, Heiko von der Leyen, Christian Veltmann, Stefan Störk, Michael Böhm, Armin Koch, Anika Großhennig, Johann Bauersachs","doi":"10.1002/ejhf.3679","DOIUrl":"https://doi.org/10.1002/ejhf.3679","url":null,"abstract":"This report presents the baseline characteristics of patients enrolled in the DIGIT-HF trial and compares them with participants from recent trials with improved outcomes in patients with heart failure (HF) and a reduced ejection fraction (HFrEF).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"121 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144097334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.","authors":"Misato Chimura,Mingming Yang,Alasdair D Henderson,Pardeep S Jhund,Kieran F Docherty,Brian L Claggett,Akshay S Desai,Gerasimos Filippatos,Grzegorz Gajos,Katharina Mueller,Andrea Glasauer,Katja Rohwedder,Prabhakar Viswanathan,Carolyn S P Lam,Naoki Sato,Michele Senni,Adriaan A Voors,Faiez Zannad,Mehmet B Yilmaz,Bertram Pitt,Muthiah Vaduganathan,Scott D Solomon,John J V McMurray,","doi":"10.1002/ejhf.3682","DOIUrl":"https://doi.org/10.1002/ejhf.3682","url":null,"abstract":"AIMSAnaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin-angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia. We evaluated the effects of finerenone according to anaemia status in patients with HFmrEF/HFpEF enrolled in FINEARTS-HF. Additionally, we examined the effect of finerenone on haemoglobin, new-onset anaemia, and resolution of anaemia during follow-up.METHODS AND RESULTSAnaemia was defined as haemoglobin <12 g/dl in women and <13 g/dl in men. The primary outcome was the composite of total (first and recurrent) heart failure events and cardiovascular death. Of 5665 patients analysed, 1584 (28.0%) had anaemia at baseline. Patients with anaemia were at higher risk of the primary endpoint compared to those without anaemia: event rate 24.3 (95% confidence interval [CI] 21.9-26.9) versus 13.1 (95% CI 12.0-14.3) per 100 person-years; rate ratio [RR] 1.67 (95% CI 1.45-1.92). Persistence of anaemia was associated with worse outcomes compared to resolution of anaemia, and patients with new-onset anaemia had worse outcomes than those who did not develop anaemia. The effect of finerenone on the primary endpoint was consistent in patients with and without anaemia (RR 0.89; 95% CI 0.73-1.10 vs. RR 0.76; 95% CI 0.64-0.91; interaction p = 0.27) and across the range of haemoglobin at baseline. Finerenone treatment did not increase the resolution of anaemia or prevent new-onset anaemia.CONCLUSIONSFinerenone reduces the risk of clinical outcomes regardless of anaemia status. Clinical Trial Registration ClinicalTrials.gov NCT04435626.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"40 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.","authors":"Jonathan W Cunningham,Brian L Claggett,Muthiah Vaduganathan,Akshay S Desai,Pardeep S Jhund,Carolyn S P Lam,Michele Senni,Sanjiv Shah,Adriaan Voors,Faiez Zannad,Bertram Pitt,Flaviana Amarante,James Lay-Flurrie,Katja Rohwedder,Laura Goea,Mario Berger,John J V McMurray,Scott D Solomon","doi":"10.1002/ejhf.3694","DOIUrl":"https://doi.org/10.1002/ejhf.3694","url":null,"abstract":"AIMSN-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations serve as markers of prognosis and therapeutic response in patients with heart failure (HF). The effect of the non-steroidal mineralocorticoid receptor antagonist finerenone on NT-proBNP in patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is currently unknown.METHODS AND RESULTSThe FINEARTS-HF trial randomized patients with HFmrEF/HFpEF and NT-proBNP ≥300 pg/ml (≥900 pg/ml if atrial fibrillation) or B-type natriuretic peptide ≥100 pg/ml (≥300 pg/ml if atrial fibrillation) to finerenone versus placebo. Core laboratory NT-proBNP was measured at baseline, 3, and 12 months after randomization. We evaluated the association between log-transformed NT-proBNP and the primary outcome (cardiovascular death and total HF events), whether baseline NT-proBNP modified the effect of finerenone on this outcome, and the effect of finerenone on NT-proBNP concentration. Baseline NT-proBNP was available in 5843 of 6001 patients analysed (median 1041 [interquartile range 449-1946] pg/ml) and was strongly associated with risk of the primary outcome (adjusted rate ratio 1.44 per doubling in biomarker concentration, 95% confidence interval [CI] 1.37-1.51], p < 0.001). Baseline NT-proBNP did not modify the benefit of finerenone on the primary outcome (pinteraction = 0.92). Finerenone reduced NT-proBNP by 12.1% (95% CI 8.5-15.4%) at 3 months and 12.5% (95% CI 8.1-16.7%) at 12 months, compared to placebo.CONCLUSIONSIn patients with HFmrEF/HFpEF, finerenone reduced NT-proBNP within months of initiation, and improved clinical outcomes regardless of baseline NT-proBNP concentration.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov NCT04435626, EudraCT 2020-000306-29.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"29 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of pulmonary artery pressure-guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta-analysis of real-world evidence with the CardioMEMS Heart Failure System.","authors":"Chris J Kapelios,Sotiria Liori,Michael Bonios,William T Abraham,Gerasimos Filippatos","doi":"10.1002/ejhf.3687","DOIUrl":"https://doi.org/10.1002/ejhf.3687","url":null,"abstract":"AIMSPulmonary artery pressure (PAP)-guided heart failure (HF) management using the CardioMEMS HF System improves patient outcomes in randomized controlled trials (RCTs). Our aim was to systematically assess its impact on outcomes of HF patients receiving the device in a non-RCT setting.METHODS AND RESULTSPubMed, ClinicalTrials.gov and Cochrane Clinical Trial Collection were searched on 8 January 2025. Studies were eligible if they included: (i) pre/post-comparison of outcomes in patients receiving CardioMEMS; (ii) adult patients diagnosed with HF; (iii) follow-up ≥6 months, and (iv) report of the primary outcome, i.e. HF hospitalization (HFH) rates. Other outcomes were changes in PAP, New York Heart Association (NYHA) class and quality of life. Quantitative analysis was performed by generating forest plots and calculating pooled means, mean differences and incidence rate ratio (IRR) by random-effect models, as appropriate. Eight studies with a total of 3306 patients were included. Four studies were single-arm, open-label, industry-funded studies and four real-world practice studies. Four studies were performed in the US and four in Europe. Significant decreases in systolic PAP (-7.8 mmHg [-10.1 mmHg; -5.6 mmHg]), mean PAP (-5.2 mmHg [-6.7 mmHg; -3.8 mmHg]) and diastolic PAP (-4.4 mmHg [-5.5 mmHg; -3.3 mmHg]) were demonstrated. One year after CardioMEMS implantation, 56% [43%; 67%] of patients were NYHA class I/II with EQ-5D-5L visual analogue scale scores being significantly improved from baseline (7.2 [3.5; 10.9]). PAP-guided HF management was associated with a significant, 61% decrease in HFHs at 1 year (IRR 0.39 [0.31; 0.47]).CONCLUSIONSHeart failure management with CardioMEMS leads to lower PAP, improved functional status and quality of life, and decrease of HFHs at 1 year in patients receiving the device in a real-life, non-RCT setting.SYSTEMATIC REVIEW REGISTRATIONPROSPERO database registration number CRD42025635206.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"96 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding the article 'Lower extremity lymphatic flow is associated with diuretic response in acute heart failure'.","authors":"Chao Yang,Beibei Gao,Jinyu Huang","doi":"10.1002/ejhf.3686","DOIUrl":"https://doi.org/10.1002/ejhf.3686","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"76 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}